Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ® in Japan.
Yusuke OkadaKazuhiro KajiyamaChieko IshiguroTakahiro NonakaTomomi KomakiWataru KugaNoriyuki KomiyamaToyotaka IguchiNaoya HoriuchiYoshiaki UyamaPublished in: The Journal of dermatological treatment (2024)
No clear increase in the risk of neutropenia with anti-IL-23 antibodies was observed.